Compare Advanced Micro Devices (AMD) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Amphastar Pharmaceuticals Inc — how do they compare? Advanced Micro Devices trades at $468.28 (market cap $766.54B), while Amphastar Pharmaceuticals Inc trades at $20.44 (market cap $863.95M). The key difference: Advanced Micro Devices is far larger — about 887.3× Amphastar Pharmaceuticals Inc's market cap, and Advanced Micro Devices is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMD | AMPH | |
|---|---|---|
Market Cap | $766.54B | $863.95M |
Sector | Technology | Health |
52-Week High | $580.91 | $30.81 |
52-Week Low | $151.14 | $16.87 |
Enterprise Value | $757.71B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $483.36, down 1.21% on the day, near its pivot point of $487 with support at $473 and resistance at $497. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $1.66 versus $1.62 expected, and revenue growth accelerating to $34.64 billion in 2025 from $25.8 billion in 2024. Operating cash flow surged to $7.71 billion in 2025, supporting investments in AI and data center segments. Technical indicators are neutral overall, with RSI levels suggesting balanced momentum.
Outlook remains positive driven by AI demand and market share gains, but high valuation multiples pose risks. Analyst consensus is bullish with a $615.11 price target, though competition and execution challenges warrant caution. The stock offers growth exposure but requires monitoring of competitive dynamics and margin sustainability.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
